Inhibitor Therapeutics, Inc. (OTC:INTI)
| Market Cap | 16.91M+71.9% |
| Revenue (ttm) | 0 |
| Net Income | -3.31M+4.0% |
| EPS | -0.02+4.5% |
| Shares Out | 172.57M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,000 |
| Open | 0.10 |
| Previous Close | 0.10 |
| Day's Range | 0.10 - 0.10 |
| 52-Week Range | 0.04 - 0.12 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About INTI
Inhibitor Therapeutics, Inc., established in 1992 and based in Tampa, Florida, is a pharmaceutical development enterprise. The company is dedicated to inventing and commercializing medical treatments for patients in the United States who suffer from various cancerous and non-cancerous cell proliferation conditions. A primary focus of their work involves advancing SUBA-Itraconazole, an oral variant of the drug itraconazole, for therapeutic applications in prostate and lung cancers. Furthermore, Inhibitor Therapeutics, Inc. has successfully completed a positive Phase 2b clinical trial for SUBA-Itraconazole in the management of basal cell carcinoma nevus syndrome. The organization was previously known as HedgePath Pharmaceuticals, Inc. until its name was officially changed in August 2019.
$INTI stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in INTI holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by INTI's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
INTI Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New INTI patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to INTI from public contracts
Source: USAspending.gov
INTI Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from INTI’s recent data — informational, not investment advice